Antibacterial, antioxidant, and cytotoxic activities of Syzygium aromaticum (L.) Merr. & Perry essential oil with identification of its chemical constituents
Abstract Aromatic plants embrace volatile compounds with efficiency in treating different diseases. In Jordan, Syzygium aromaticum flower buds (clove) are extensively used as folk medicine without awareness of its bio-safe dosage. Herein, clove buds were hydrodistilled using the Clevenger apparatus, and the resulting essential oil (CEO) was analyzed using Gas Chromatography-Mass Spectrometry (GC-MS). The antibacterial activity was evaluated against tested bacterial strains by agar diffusion test and micro-broth dilution assay. The antioxidant capacity was assessed using DPPH radical scavenging assay, while the cytotoxic potency was unraveled by determination of its anti-proliferative activity against MDA-MB-231 breast adenocarcinoma and normal Vero cell lines. CEO yield was 5.7 ± 1.3% (w/w); encompassed 24 volatile ingredients with eugenol as the principal compound (73.41%). The CEO inhibited the growth of both Gram-positive and Gram-negative bacterial test strains, causing the formation of 13.7 ± 1.5–17.3 ± 0.6 mm and 11.7 ± 1.5–20.7 ± 1.2 mm inhibition zones, respectively with MIC 1.25–5 μL/mL. Moreover, it showed antioxidant activity with $ IC_{50} $ 0.0016 ± 0.0001 μL/mL (1.6 ± 0.1 μg/mL, 2.98 ± 0.4 µg $ Trolox^{®} $/µg CEO). Intriguingly, the CEO was cytotoxic against both cancerous and noncancerous cell lines at $ IC_{50} $ of 0.25 ± 0.02 μL/mL and 0.18 ± 0.01 μL/mL, respectively. Herein results unveil the potential application of CEO as a pharmaceutical remedy with considering its bio-safe dosage..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Zeitschrift für Naturforschung / C - 78(2022), 3-4 vom: 23. Mai, Seite 105-112 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al-Zereini, Wael A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2022 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/znc-2022-0056 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009151044 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009151044 | ||
| 003 | DE-627 | ||
| 005 | 20231205155407.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230813s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/znc-2022-0056 |2 doi | |
| 035 | |a (DE-627)GRUY009151044 | ||
| 035 | |a (DE-B1597)znc-2022-0056-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.00 |2 bkl | ||
| 084 | |a 35.70 |2 bkl | ||
| 100 | 1 | |a Al-Zereini, Wael A. |e verfasserin |0 (orcid)0000-0002-7671-0426 |4 aut | |
| 245 | 1 | 0 | |a Antibacterial, antioxidant, and cytotoxic activities of Syzygium aromaticum (L.) Merr. & Perry essential oil with identification of its chemical constituents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract Aromatic plants embrace volatile compounds with efficiency in treating different diseases. In Jordan, Syzygium aromaticum flower buds (clove) are extensively used as folk medicine without awareness of its bio-safe dosage. Herein, clove buds were hydrodistilled using the Clevenger apparatus, and the resulting essential oil (CEO) was analyzed using Gas Chromatography-Mass Spectrometry (GC-MS). The antibacterial activity was evaluated against tested bacterial strains by agar diffusion test and micro-broth dilution assay. The antioxidant capacity was assessed using DPPH radical scavenging assay, while the cytotoxic potency was unraveled by determination of its anti-proliferative activity against MDA-MB-231 breast adenocarcinoma and normal Vero cell lines. CEO yield was 5.7 ± 1.3% (w/w); encompassed 24 volatile ingredients with eugenol as the principal compound (73.41%). The CEO inhibited the growth of both Gram-positive and Gram-negative bacterial test strains, causing the formation of 13.7 ± 1.5–17.3 ± 0.6 mm and 11.7 ± 1.5–20.7 ± 1.2 mm inhibition zones, respectively with MIC 1.25–5 μL/mL. Moreover, it showed antioxidant activity with $ IC_{50} $ 0.0016 ± 0.0001 μL/mL (1.6 ± 0.1 μg/mL, 2.98 ± 0.4 µg $ Trolox^{®} $/µg CEO). Intriguingly, the CEO was cytotoxic against both cancerous and noncancerous cell lines at $ IC_{50} $ of 0.25 ± 0.02 μL/mL and 0.18 ± 0.01 μL/mL, respectively. Herein results unveil the potential application of CEO as a pharmaceutical remedy with considering its bio-safe dosage. | ||
| 700 | 1 | |a Al-Trawneh, Ibrahim N. |4 aut | |
| 700 | 1 | |a Al-Qudah, Mahmoud A. |4 aut | |
| 700 | 1 | |a TumAllah, Heba M. |4 aut | |
| 700 | 1 | |a Abudayeh, Zead H. |4 aut | |
| 700 | 1 | |a Hijazin, Tahani |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zeitschrift für Naturforschung / C |d De Gruyter, 1973 |g 78(2022), 3-4 vom: 23. Mai, Seite 105-112 |h Online-Ressource |w (DE-627)GRUY000016527 |w (DE-600)2078107-6 |w (DE-576)101177968 |x 1865-7125 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2022 |g number:3-4 |g day:23 |g month:05 |g pages:105-112 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/znc-2022-0056 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 42.00 |j Biologie: Allgemeines |q VZ |
| 936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 78 |j 2022 |e 3-4 |b 23 |c 05 |h 105-112 | ||